top of page
Executive Spotlights

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO

Waltham, MA, November 27, 2023 (PRNewswire) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, has announced its name change to Spyre Therapeutics, Inc. Effective from the market open on November 28, 2023, Spyre will be listed on Nasdaq under the ticker symbol "SYRE." The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the Company in June 2023. Reflecting the Company's ambition to achieve enhanced efficacy and convenience in Inflammatory Bowel Disease (IBD) therapies, Spyre aims to develop a next generation of IBD products. This involves combining best-in-class antibody engineering, rational therapeutic combinations, and precision patient selection approaches to improve efficacy for patients. The Company also announced today the appointment of Cameron Turtle, DPhil as Chief Executive Officer (CEO).

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page